Eli Lilly CEO David Ricks joins CNBC’s Meg Tirrell and the ‘Squawk Box’ team to break down the company’s latest earnings report and its clinical trial results for weight-loss drug tirzepatide.
Eli Lilly CEO David Ricks breaks down Q1 earnings, obesity drug trial results
Tweet on Twitter
Share on Facebook
Pinterest
